The Cause of Alzheimer's Might Be Coming From Inside Your Mouth
While the exact mechanisms of this infection are something researchers are still trying to isolate, numerous studies suggest the deadly spread of Alzheimer's goes way beyond what we used to think.
One such study, published in 2019, suggested what could be one of the most definitive leads yet for a bacterial culprit behind Alzheimer's, and it comes from a somewhat unexpected quarter: gum disease.
In a paper led by senior author Jan Potempa, a microbiologist from the University of Louisville, researchers reported the discovery of Porphyromonas gingivalis – the pathogen behind chronic periodontitis (aka gum disease) – in the brains of deceased Alzheimer's patients.
P. gingivalis' gingipains (red) among neurons in the brain of a patient with Alzheimer's. (Cortexyme)
It wasn't the first time the two factors have been linked, but the researchers went further.
In separate experiments with mice, oral infection with the pathogen led to brain colonization by the bacteria, together with increased production of amyloid beta (Aβ), the sticky proteins commonly associated with Alzheimer's.
The research team, coordinated by pharma startup Cortexyme, which was co-founded by first author Stephen Dominy, wasn't claiming to have discovered definitive evidence of Alzheimer's causation.
But it was clear they thought we had a strong line of investigation here.
"Infectious agents have been implicated in the development and progression of Alzheimer's disease before, but the evidence of causation hasn't been convincing," Dominy said at the time.
"Now, for the first time, we have solid evidence connecting the intracellular, Gram-negative pathogen, P. gingivalis, and Alzheimer's pathogenesis."
In addition, the team identified toxic enzymes called gingipains secreted by the bacteria in the brains of Alzheimer's patients, which correlated with two separate markers of the disease: the tau protein, and a protein tag called ubiquitin.
But even more compellingly, the team identified these toxic gingipains in the brains of deceased people who were never diagnosed with Alzheimer's.
That's important, because while P. gingivalis and the disease have been linked before, it's never been known – to put it simply – whether gum disease causes Alzheimers, or whether dementia leads to poor oral care.
The fact that low levels of gingipains were evident even in people who were never diagnosed with Alzheimer's could be a smoking gun – suggesting they might have developed the condition if they had lived longer.
"Our identification of gingipain antigens in the brains of individuals with AD and also with AD pathology but no diagnosis of dementia argues that brain infection with P. gingivalis is not a result of poor dental care following the onset of dementia or a consequence of late-stage disease, but is an early event that can explain the pathology found in middle-aged individuals before cognitive decline," the authors explained in their paper.
Further, a compound formulated by the company called COR388, showed in experiments with mice that it could reduce bacterial load of an established P. gingivalis brain infection, while also reducing amyloid-beta production and neuroinflammation.
We'll have to wait and see what future research will uncover about this link, but the research community is cautiously optimistic.
"Drugs targeting the bacteria's toxic proteins have so far only shown benefit in mice, yet with no new dementia treatments in over 15 years it's important that we test as many approaches as possible to tackle diseases like Alzheimer's," chief scientific officer David Reynolds from Alzheimer's Research commented in a statement.
The findings were reported in Science Advances.
An earlier version of this story was published in January 2019.
Your Scented Wax Melts Can Pollute Indoor Air as Much as a Diesel Engine
Your Takeaway Food Packaging Could Increase Your Risk of Heart Failure
Study Reveals How This Artificial Sweetener May Cause Heart Damage
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
3 hours ago
- San Francisco Chronicle
The U.S. is losing its biotech edge over China — and that's bad news for the Bay Area
From gene therapies to cancer breakthroughs, California has been the driving force behind America's biotechnology industry. But today, that edge is slipping. A National Security Commission on Emerging Biotechnology report to Congress in April stated that the U.S. is dangerously close to falling behind China in biotechnology innovation, and called for urgent investment and strategic coordination to maintain global leadership. Genentech's founding in 1976 in South San Francisco marked the start of the modern biotech era, and, ever since, California has been at the forefront of countless scientific discoveries and medical innovations. However, recent funding cuts and an overreliance on China for manufacturing pipelines leave our nation vulnerable. As the report urges, the U.S. must prioritize biotechnology at the national level or risk relying on China to use this strategic power for good. In 2011, the Chinese government declared biotechnology a ' strategic emerging industry ' and has since committed billions to secure dominance in areas like synthetic biology, gene editing and biomanufacturing. In 2024 alone, China conducted over 7,100 clinical drug trials, surpassing the United States and accounting for nearly 40% of global trial activity. Despite U.S. tariffs under the Trump administration designed to counter China's economic influence, China's gross domestic product has remained strong, fueling even greater investment in strategic sectors like biotechnology. By contrast, the U.S. continues to lose ground, constrained by outdated regulatory frameworks and a lack of coordinated federal strategy. While China is building a biotech empire with deliberate, state-backed coordination, the U.S. is stuck playing defense with shrinking budgets. U.S. federal support for biomedical research is slipping, with the budget for the National Institutes of Health facing a 40% cut in the coming year. For a region like the Bay Area, home to some of the world's most promising biotech startups and research institutions, these cuts have a direct toll, including the termination of $314 million in funding that was to be used to train the next generation of biomedical and health researchers. Major institutions like UCSF, Stanford and UC Berkeley are now bracing for delayed projects, staffing freezes and reductions in early-career fellowships that are vital to sustaining long-term innovation. On a national level, promising studies have been halted midstream, leaving research gaps in breakthrough treatments for cancer, Alzheimer's disease and other major infectious diseases that impact millions of Americans. When U.S. investment in domestic biotech falters, it slows innovation at home and creates an opening for global competitors to step in. China's government is strategically positioning its biotech sector to fill the gap left by stalled American research. Just last month, U.S. pharmaceutical firms signed 14 licensing deals with Chinese biotech companies worth up to $18.3 billion, underscoring our growing dependence on China's rapidly maturing R&D capabilities. This shift carries significant implications for California. It is home to over 16,500 life sciences companies and establishments, more than any other state, according to the California Biotechnology Foundation. The state directly employs more than 466,000 workers and generates more than $414 billion in annual economic output. In 2023, California led the nation in venture capital investment, raising over $34 billion for life science companies. Further, California accounted for 40% of all U.S. life sciences patents filed in 2023, and more bioscience patents are issued to California researchers than to those in any other state. Losing ground to China isn't just an economic risk; it's also a national security threat that could reshape who controls the future of health care. While the U.S. system is built on competition and patient outcomes, China's state-controlled model prioritizes strategic control and global influence. In America, ethical safeguards, transparency and regulatory review shape medical progress. In China, the government's control allows for faster approvals but also looser oversight, creating the risk of untested or misused science. The National Security Commission on Emerging Biotechnology warned that China's biotech advances could be weaponized — from battlefield-ready biologics to more nefarious applications. As a scientist working in biotechnology in the Bay Area, I understand that California plays a central role in this global race. From early-stage research in university labs to large-scale manufacturing by leading biotech firms, the state's infrastructure, talent and capital drive America's competitiveness. The Bay Area remains one of the most dense and productive biotech ecosystems in the world, thanks to its concentration of top-tier research institutions, world-class hospitals, a culture of entrepreneurship and the ability to attract the world's best and brightest to its academic and industrial ecosystem. But even here, the warning signs are hard to ignore. Federal NIH cuts have already disrupted major research projects at UC campuses, impacting our ability to attract talented students to our graduate and postdoctoral research programs, while venture capital is increasingly eyeing faster-moving regulatory environments abroad, preferring to license in late-stage assets from China instead of funding early-stage research at home. If Washington fails to prioritize a national biotech strategy, California's innovation engine could slow just as competitors abroad gain momentum. The state's economic future, public health leadership and ability to attract global talent are all at stake. China is no longer a distant biotech challenger and is actively reshaping the industry with its speed, regulatory agility and cost-efficiency, shifting the innovation center of gravity away from the U.S. The National Security Commission on Emerging Biotechnology has made clear that this is not just a matter of competition, but a strategic threat with long-term consequences for public health and national security. If America is to remain a global leader in biotechnology, we must urgently invest in our domestic research ecosystem and rebuild the infrastructure that has powered decades of discovery or be forced to surrender it to a rival that plays by different rules. Ash Jogalekar is a scientist and science writer based in the Bay Area. He is a scientist in residence at the Oppenheimer Project and works on emerging threats and technology risks in areas like biotechnology and AI.
Yahoo
2 days ago
- Yahoo
Fiona Phillips' husband reveals they were living ‘separate lives' before Alzheimer's diagnosis
Fiona Phillips' husband Martin Frizell has revealed they were living 'separate lives' before her Alzheimer's diagnosis. The former GMTV host, 64, announced in 2023 that she had been diagnosed with early onset dementia, after initially mistaking her 'brain fog and anxiety' for menopause symptoms. In her new memoir, Remember When: My Life With Alzheimer's, Frizell, 66, has shared how the couple struggled and grew apart in the years leading up to her diagnosis. 'Nothing I could say seemed to help,' he said of the tough period, which began around 2015, according to an extract obtained by the Daily Mail. 'And I guess like in any relationship, the whole thing spirals. Because I felt she was being moody and critical of everything I said and did, I shut down too. 'We were barely talking and while we were still in the same house we were living quite separate lives.' Frizell recalled experiencing 'long silences' with his wife of 28 years when they were at home in the evenings - but didn't think it was a symptom of the menopause or Azheimer's. 'I just thought we had hit the wall that so many marriages do as the kids get older – ours were now well into their teens – and maybe as a couple we had just run our course,' he admitted. Since the diagnosis, Frizell has taken on complete responsibility for the household, from paying bills to chores, which he said he used to 'take for granted.' To help alleviate some of the pressure from himself and their 23-year-old son MacKenzie, he hired a trained carer. Recently, Frizell recalled how Phillips thought he had kidnapped her because of 'delusions' brought on by the disease. In November 2024, he announced he would be stepping down as editor of ITV's This Morning in order to support his wife, after more than a decade of service. At the time, he wrote: 'Next year I'm expecting my family priorities to change, so I need to free up time for them.' As of January 2025, he helps Phillips 'brush her teeth and shower', dress herself, eat and drink. On difficult days where his wife has experienced moments of 'extreme confusion', he shared that she has demanded to see her late parents. Phillips, who lost her mother to Alzheimer's aged 74 in 2006, previously shared her concerns about how people will 'perceive' her. 'There is still an issue with this disease that the public thinks of old people, bending over a stick, talking to themselves,' she told The Mirror. 'But I'm still here, getting out and about, meeting friends for coffee, going for dinner with Martin, and walking every day.'
Yahoo
2 days ago
- Yahoo
Metallic nanoflowers heal brain cells and extend lifespan in stunning new research
A team at Texas A&M AgriLife Research has developed a new way to protect and potentially heal brain cells, using microscopic particles shaped like flowers. The so-called 'nanoflowers,' metallic nanoparticles engineered at the molecular scale, appear to restore the function of mitochondria, the cellular engines that power our bodies. The study suggests this could lead to a new class of neurotherapeutic drugs. Instead of just masking symptoms of conditions like Parkinson's or Alzheimer's, nanoflowers may target the root cause, mitochondrial dysfunction. 'These nanoflowers look beautiful under a microscope, but what they do inside the cell is even more impressive,' said Dr. Dmitry Kurouski, associate professor at Texas A&M and lead investigator on the project. The research was led by Charles Mitchell, a doctoral student in the university's biochemistry and biophysics department, and Mikhail Matveyenka, a research specialist. Both work in Kurouski's lab at the Texas A&M AgriLife Institute for Advancing Health through Agriculture. Molecular fix for brain health Mitochondria convert food into energy for cells. But in the process, they also generate harmful byproducts like reactive oxygen species, unstable molecules that can accumulate and cause damage. To test the therapeutic potential of nanoflowers, the team exposed neurons and astrocytes, supportive brain cells, to two different types of nanoflowers. After 24 hours, cells showed improved mitochondrial structure and quantity, along with a significant drop in oxidative stress. 'Even in healthy cells, some oxidative stress is expected,' Kurouski said. 'But the nanoflowers seem to fine-tune the performance of mitochondria, ultimately bringing the levels of their toxic byproducts down to almost nothing.' According to Kurouski, healthier mitochondria could lead to better brain function overall. 'If we can protect or restore mitochondrial health, then we're not just treating symptoms—we're addressing the root cause of the damage,' he added. Worm model shows lifespan boost The team expanded the study beyond isolated cells and into live organisms using Caenorhabditis elegans, a tiny worm commonly used in brain research. Worms treated with nanoflowers not only lived several days longer than untreated ones, but also showed lower mortality early in life. The findings strengthen the case for nanoflowers as neuroprotective agents. Kurouski's team now plans to test their safety and distribution in more complex animal models before considering human trials. Despite years of research, drugs that protect neurons from degeneration remain rare. Most treatments focus on reducing symptoms rather than halting disease progression. Kurouski believes this work could flip that script. 'We think this could become a new class of therapeutics,' he said. 'We want to make sure it's safe, effective and has a clear mechanism of action. But based on what we've seen so far, there's incredible potential in nanoflowers.' Texas A&M Innovation has filed a patent application for the use of nanoflowers in brain health treatments. Kurouski's team plans to collaborate with the Texas A&M College of Medicine to explore further applications, including stroke and spinal cord injury recovery. The study is published in the Journal of Biological Chemistry. Solve the daily Crossword
